Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

CHUV Centre Hospitalier Universitaire Vaudois ( Site 2602), Lausanne

Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 2603), Geneva

Melanoma Institute Australia ( Site 2402), Wollstonecraft

Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 2863), Sandton

Calvary Mater Newcastle-Medical Oncology ( Site 2404), Waratah

Tasman Oncology Research Pty Ltd ( Site 2403), Southport

CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2865), Port Elizabeth

Fiona Stanley Hospital ( Site 2401), Murdoch

Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ ( Site 2221), Szeged

Cape Town Oncology Trials ( Site 2864), Cape Town

Universitaetsspital Zuerich ( Site 2601), Zuerich Flughafen

NYU Clinical Cancer Center ( Site 2002), New York

R.J. Zuckerberg Cancer Center ( Site 2032), Lake Success

Hopital La Timone ( Site 2103), Marseille

University of Pennsylvania Abramson Cancer Center ( Site 2008), Philadelphia

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2399), Milan

Istituto Europeo di Oncologia ( Site 2301), Milan

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 2022), Baltimore

Inova Schar Cancer Institute ( Site 2011), Fairfax

Duke Cancer Institute ( Site 2005), Durham

Hospital Universitario Ramón y Cajal ( Site 2802), Madrid

Institut Claudius Regaud ( Site 2105), Toulouse

University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 2026), Gainesville

CHU de Bordeaux- Hopital Saint Andre ( Site 2108), Bordeaux

Istituto Oncologico Veneto IRCCS ( Site 2355), Padua

West Cancer Center - East Campus ( Site 2014), Germantown

Martha Morehouse Tower ( Site 2020), Columbus

Policlinico Le Scotte - A.O. Senese ( Site 2377), Siena

C.H. Lyon Sud ( Site 2102), Pierre-Bénite

A.P.H. Paris, Hopital Saint Louis ( Site 2107), Paris

Mays Cancer Center ( Site 2025), San Antonio

University of Colorado, Anschutz Cancer Pavilion ( Site 2012), Aurora

Istituto Nazionale Tumori Fondazione Pascale ( Site 2302), Napoli

The Angeles Clinic and Research Institute ( Site 2009), Los Angeles

UCLA Hematology & Oncology ( Site 2004), Los Angeles

Providence Saint John's Health Center ( Site 2010), Santa Monica

Gustave Roussy ( Site 2101), Villejuif

Oregon Health & Science University ( Site 2013), Portland

Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 2261), Bogotá

Fundación Valle del Lili ( Site 2265), Santiago de Cali

IC La Serena Research ( Site 2254), La Serena

HaEmek Medical Center ( Site 2703), Afula

Rambam Health Care Campus-Oncology ( Site 2704), Haifa

CIDO SpA-Oncology ( Site 2256), Temuco

Rabin Medical Center-Oncology ( Site 2705), Petah Tikva

Chaim Sheba Medical Center ( Site 2701), Ramat Gan

FALP-UIDO ( Site 2251), Santiago

Oncovida ( Site 2257), Santiago

Bradfordhill ( Site 2252), Santiago

Hadassah Ein Karem Jerusalem ( Site 2702), Jerusalem

Clinica Adventista Belgrano-Oncology ( Site 2242), Caba.

Instituto Alexander Fleming-Alexander Fleming ( Site 2243), Buenos Aires

Sanatorio Finochietto ( Site 2245), Buenos Aires

"General Hospital of Athens Laiko-First Department of Internal Medicine ( Site 2212)", Athens

European Interbalkan Medical Center-Oncology Department ( Site 2211), Thessaloniki

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2233), Warsaw

Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 2231), Gdansk

Steve Biko Academic Hospital-Medical Oncology ( Site 2862), Pretoria

LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 2861), Pretoria

HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Site 2801), Barcelona